Tagged with M

Genzyme de Colombia S.A. What is the role, significance, and importance of the Colombian market within the larger global strategy of Genzyme international? Colombia is a very important country because we have a market with a well developed, and in that way different, health system from other countries in the Andean region. Of course…

Chamber of Commerce “Polish Pharmacy” The pharmaceutical industry market growth, including generics and originator drugs, is today steady and sustainable. The market size is over 5 billion Euros which makes Poland the 6th biggest market in Europe. What are the competitive advantages do you see in the Polish market compared to other European countries? First,…

Bayer Schering Pharma The 2006 acquisition of Schering by Bayer is a prime example of the way that big pharma is now approaching growth through acquisition in this extremely competitive and challenging global market. Given that the company seems to be finished with mergers and acquisitions for the time being, what are Bayer…

Daiichi Sankyo Germany DAIICHI SANKYO in Germany, Austria and Switzerland DAIICHI SANKYO wants to be a Global Pharma Innovator with Germany at the center of this process on the European continent. An example of this development is your manufacturing facility in Pfaffenhofen, a basis to export to more than 50 countries. Can you…

Farma De Colombia Having just recently celebrated its 50th anniversary in Colombia, how would you describe Farma de Colombia’s unique business model and what have been its keys to its success? We are a brand company. We build marks and brands. While we do sell to the government, our main strength lies in…

Nycomed France Nycomed lost an important patent with Pantoprazole in the middle of 2009, which has undoubtedly warranted some restructuring. What has been the impact of this loss on business in France, and how are you preparing for the future? Losing exclusivity with Pantoprazole is huge as it was 70% of our…

ITF-Labomed Labomed was bought by Italfarmaco in 2009, but aside from that, what have been the main milestones and achievements of Labomed since its creation in 1968? When I came to Labomed in 1997, I began a process of renewing the company’s product portfolio and changing the overall profile of Labomed.…

Novartis De Colombia S.A. Being an industry giant with operations in over one hundred counties worldwide, what is the role and significance of Colombia for Novartis global? As a global company, our overall mission is to discover, develop, and successfully market innovative products to prevent and cure diseases; to ease suffering; and to enhance…

Meizler Biopharma There is little publicly available information on your personal history and the founding of Meizler. Can you share that story for our readers? Everybody has a story – unless they’re second generation, of course! I am an architect by training. Before entering the pharmaceutical industry I owned an engineering and…

Hypermarcas Hypermarcas is a huge, diversified corporation that sells everything from shampoo, to medicine. Would you consider it more of a consumer goods company that happens to sell pharmaceuticals, or the other way around? The company´s focus is on Health, Personal Care and Beauty products. In Brazil, the combination of these…

Romanian Association of International Drug Manufacturers (ARPIM) While, today, you are in charge of voicing the concerns of the innovators in the country, let us first take a step back and see what attracted these companies to Romania in the first place. Can you tell our readers more about the key factors of attraction in that sense?…

Chiesi Pharmaceuticals BV The Dutch affiliate of Chiesi was established in 2007 when many changes were occurring in the local industry. The new healthcare system policy went into effect and the market was shifting towards a cost-containment structure. What drove Chiesi’s decision to start-up in the Netherlands? Our respiratory product, Foster, was one…